Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022
Cyteir Therapeutics, Inc. (Nasdaq: CYT) will host a virtual R&D Day on April 26, 2022, at 8:30 a.m. ET. The event will feature discussions on the research identifying the molecular target of CYT-0851 and an overview of the ongoing clinical plan. The audio webcast will be available on Cyteir's website and archived for 30 days post-event. Cyteir focuses on developing next-generation synthetically lethal therapies for cancer, with CYT-0851 currently in a Phase 1/2 trial for hematologic and solid tumors.
- None.
- None.
The live audio webcast can be accessed via the Investor Relations section of the Company’s website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir’s website for 30 days.
About
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005211/en/
INVESTOR:
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com
MEDIA:
925-429-1850
mparisi@forwardhealthinc.com
Source:
FAQ
What is Cyteir Therapeutics hosting on April 26, 2022?
What will be discussed during Cyteir's R&D Day?
Where can I access the webcast for Cyteir's R&D Day?
How long will the archived webcast of Cyteir's R&D Day be available?
What is CYT-0851 and its current status?
